Bismuth and Antimony Complexes, Acid Blockers, and Helicobacter pylori Therapy
This community develops chemical compounds for treating stomach acid disorders and eradicating Helicobacter pylori infection, while also studying the structural bonding of main-group metal complexes.
The research focuses on synthesizing bismuth and antimony complexes, often involving chalcogen or halogen bonding interactions, to create effective acid blockers. A major application is the design of quadruple and dual therapy regimens for H. pylori eradication, frequently incorporating bismuth salts or potassium-competitive acid blockers. The work includes randomized controlled trials comparing these regimens against standard proton pump inhibitor therapies, alongside the crystallographic characterization of the resulting molecular structures.
Bismuth research accounts for 7.6% of all bismuth literature, representing 2,474 papers in this group. Antimony follows with 6.9% of its research, comprising 1,404 papers, while indium contributes 4.7% of its literature with 1,738 papers.
The community comprises 13,183 papers, primarily published in Tetrahedron Letters, Inorganic Chemistry, and the Journal of Organometallic Chemistry. Recent work includes the Taipei Global Consensus on H. pylori screening, trials of rifasutenizol-based triple therapy, and bismuth-photocatalysed coupling reactions.
Papers behind this description
- Helicobacter pylori infection — Nature Reviews Disease Primers, 2023 — doi:10.1038/s41572-023-00431-8
- ACG Clinical Guideline: Treatment of Helicobacter pylori Infection — The American Journal of Gastroenterology, 2024 — doi:10.14309/ajg.0000000000002968
- Biological evaluations and biomolecular interactions along with computational insights of arylidene isatin hydrazones synthesized using nanocatalyst — Scientific Reports, 2025 — doi:10.1038/s41598-025-26721-7
- Eradication Therapy to Prevent Gastric Cancer in Helicobacter pylori–Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies — Gastroenterology, 2025 — doi:10.1053/j.gastro.2024.12.033
- Helicobacter pylori antibiotic resistance: a global challenge in search of solutions — Gut, 2025 — doi:10.1136/gutjnl-2025-335523
- AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review — Gastroenterology, 2024 — doi:10.1053/j.gastro.2024.06.038
- Halogen bonding in supramolecular chemistry: From molecular components to assembled structures — Coordination Chemistry Reviews, 2025 — doi:10.1016/j.ccr.2025.216488
- Screening and eradication of Helicobacter pylori f or gastric cancer prevention: Taipei Global Consensus II — Gut, 2025 — doi:10.1136/gutjnl-2025-336027
- Potential optical molecular switch: Lithium@cyclo[18]carbon complex transforming between two stable configurations — Carbon, 2022 — doi:10.1016/j.carbon.2021.11.005
- Synthesis of a stable crystalline nitrene — Science, 2024 — doi:10.1126/science.adp4963
- Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments — Current Gastroenterology Reports, 2024 — doi:10.1007/s11894-024-00939-3
- Bismuth Redox Catalysis: An Emerging Main-Group Platform for Organic Synthesis — ACS Catalysis, 2022 — doi:10.1021/acscatal.1c04897
- Synthesis of Phenylenediamines via (4 + 1 + 1) Photocycloaddition of 1,3-Dienes and Isocyanides Enabled by a Gallium(I)/(III) Redox: The Key Role of a Phenalenyl-Based Ligand — Journal of the American Chemical Society, 2025 — doi:10.1021/jacs.5c15802
- Halogen bonding in functional chiral systems — Chemical Society Reviews, 2026 — doi:10.1039/d5cs00938c
- Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial — The Lancet Infectious Diseases, 2025 — doi:10.1016/s1473-3099(25)00438-400438-4)
- The impact of probiotics on Helicobacter pylori eradication with bismuth quadruple therapy: A systematic review and meta-analysis — International Journal of Antimicrobial Agents, 2025 — doi:10.1016/j.ijantimicag.2025.107600
- Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors — European Journal of Clinical Pharmacology, 2025 — doi:10.1007/s00228-025-03912-9
- Therapeutic advances and future directions in Helicobacter pylori eradication — Frontiers in Microbiology, 2025 — doi:10.3389/fmicb.2025.1652943